Please see below - great opportunity from the US National Institute of Allergy and Infectious Diseases! Please circulate to anyone who may be interested. Kindly note I do not have further information about this opportunity so please consult NIAID directly with any questions or applications.
Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics
The purpose of this Notice is to announce that the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) are encouraging new applications to support translational research and development of rapid point-of-care diagnostics that will diagnose active viremic HCV infections. Applicants are encouraged to consult the target product profile for HCV diagnostics published by Reipold et al., BMC Infectious Diseases 2017, 17(Suppl 1):707. DOI 10.1186/s12879-017-2770-5, https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2770-5 for additional preferred assay qualities and characteristics.
Application and Submission Information
This notice applies to due dates on or after January 5, 2020 and subsequent receipt dates through January 8, 2023.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs):
- PA-19-272 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- PA-19-270 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed
- PA-19-053 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-19-056 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)